Screener
Adaptive Biotechnologies ADPT Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation and benefits | 6,217 | 16,992 |
| Current portion of operating lease liabilities | 8,513 | 8,920 |
| Current portion of deferred revenue | 49,397 | 45,194 |
| Current portion of revenue interest liability, net | 5,804 | 4,642 |
| Total current liabilities | 87,011 | 89,915 |
| Long-term liabilities | ||
| Operating lease liabilities, less current portion | 69,115 | 70,228 |
| Deferred revenue, less current portion | 807 | 1,006 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's current debt?
- Adaptive Biotechnologies (ADPT) reported current debt of $5.8M in Q1 2026.
- How has Adaptive Biotechnologies's current debt changed year-over-year?
- Adaptive Biotechnologies's current debt increased by 188.6% year-over-year, from $2.01M to $5.8M.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Adaptive Biotechnologies's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude